title: Assessment of tenascin-C levels in ventricular noncompaction/hypertrabeculation patients: a cross-sectional study.
abstract: OBJECTIVE
  Ventricular noncompaction/hypertrabeculation (NC/HT) is a rare form of congenital cardiomyopathy. We aimed to investigate the presence of serum tenascin-C (TN-C) in adult patients with NC/HT and evaluate its value.
  
  
  RESULTS
  Serum TN-C levels were measured by ELISA in 50 NC/HT patients both with/without systolic dysfunction and in 23 normal controls. Systolic dysfunction was defined as ejection fraction (EF) ≤ 40. Mann-Whitney U-test and ROC curve analysis were done. Of 49 NC/HT patients, 24 (49%) patients had systolic dysfunction (mean age 36 ± 15) and 25 patients (51%) had normal systolic function (mean age 36 ± 17). The ages between groups were not different. The mean levels of serum TN-C in patients with or without systolic dysfunction were 26 ± 10 ng/mL and 26 ± 8 ng/mL respectively, compared to normal controls, 7 ± 2 ng/mL (P < 0.001). No significance was observed between 2 groups of NC/HT patients regarding TN-C levels (P = 0.8). The ROC curve analysis revealed that a TN-C value of 11.7 ng/mL identified patients with NC/HT with 100% sensitivity and specifity.
  
  
  CONCLUSIONS
  High serum TN-C levels are present in adult NC/HT cardiomyopathy even when left ventricular systolic function remains normal. Also, serum TN-C levels could be regarded as a candidate biomarker in the diagnosis of NC/HT which needs to be tested in larger prospective studies.
authors.affiliation: Department of Cardiology, Istanbul Siyami Ersek Thoracic and Cardiovascular Surgery Center Training and Research Hospital, Istanbul, Turkey.
authors.forename: Hatice Betul
authors.initials: HB
authors.lastname: Erer
authors.forename: Tolga Sinan
authors.initials: TS
authors.lastname: Guvenc
authors.forename: Ahu Sarbay
authors.initials: AS
authors.lastname: Kemik
authors.forename: Hale
authors.initials: H
authors.lastname: Yilmaz
authors.forename: Seref
authors.initials: S
authors.lastname: Kul
authors.forename: Servet
authors.initials: S
authors.lastname: Altay
authors.forename: Dilaver
authors.initials: D
authors.lastname: Oz
authors.forename: Gonul
authors.initials: G
authors.lastname: Zeren
authors.forename: Ahmet
authors.initials: A
authors.lastname: Ekmekci
authors.forename: Aycan Esen
authors.initials: AE
authors.lastname: Zencirci
authors.forename: Nurten
authors.initials: N
authors.lastname: Sayar
authors.forename: Mehmet
authors.initials: M
authors.lastname: Eren
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D009202:Cardiomyopathies / Q000097:blood* / Q000151:congenital* / Q000175:diagnosis; D003430:Cross-Sectional Studies; D005260:Female; D006330:Heart Defects, Congenital / Q000097:blood* / Q000175:diagnosis*; D006801:Humans; D008297:Male; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D019063:Tenascin; D014463:Ultrasonography
chemical_list: D015415:Biomarkers; D019063:Tenascin
keywords: cardiomyopathy; hypertrabeculation; noncompaction; tenascin-C